Source documents

# The Paul–Fauci Record: A Chronological Research Report on Senator Rand Paul and Dr. Anthony Fauci's COVID-19 Interactions (2019–2026)

**Scope.** This report documents, in chronological order, the interactions between U.S. Senator Rand Paul (R-Ky.) and his Senate office/staff on one side, and Dr. Anthony Fauci (Director, National Institute of Allergy and Infectious Diseases, 1984–2022) and NIH/NIAID on the other, concerning COVID-19 origins, gain-of-function research funding, and related public-health policy disputes, from the relevant pre-2019 background through the present.

**Report date:** July 28, 2026.

**Neutrality statement.** This report takes no position on any disputed question it records — including whether NIH-funded work at the Wuhan Institute of Virology constituted "gain-of-function" research, whether Dr. Fauci's congressional testimony was accurate, or how SARS-CoV-2 emerged. It presents what each side said, what the documents show, and where the records conflict, without resolving those conflicts.

**Source-hierarchy statement.** Wherever possible, statements are quoted verbatim from primary sources in this order of preference: (1) official government records (govinfo/GPO printed hearing transcripts, official letters, agency reports); (2) official video (C-SPAN, Senate ISVP webcasts) and broadcast transcripts; (3) contemporaneous news reporting across the spectrum; (4) later retrospectives, memoirs, and fact-checks. Where a quote could not be verified against a primary source, it is marked UNVERIFIED and the source of the quotation is identified.

**Note on the July 29, 2026 hearing.** The Senate Homeland Security and Governmental Affairs Committee hearing "Testimony of Anthony Fauci" is scheduled for July 29, 2026 — the day after this report's date. It had **NOT yet occurred** at report time. This report covers its scheduling, the subpoena history, and expected topics; no outcomes can be reported.

---

## Executive Summary

The Paul–Fauci relationship began as a policy disagreement and escalated, over six years, into the most sustained confrontation between a sitting senator and a public-health official in modern congressional history. Their first documented COVID-19 exchange came on May 12, 2020, at a Senate HELP Committee hearing, when Paul told Fauci, "I don't think you are the end-all," and Fauci replied that he had "never made myself out to be the end-all." Through the remainder of 2020 the two clashed over school reopening, lockdowns, New York's mortality statistics, and natural immunity. The conflict's center of gravity shifted decisively in 2021, when Paul began pressing Fauci on NIH funding of coronavirus research at the Wuhan Institute of Virology (WIV) through the EcoHealth Alliance grant R01AI110964 — a line of questioning that produced Fauci's flat denial on May 11, 2021 ("the NIH has not ever and does not now fund gain-of-function research in the Wuhan Institute of Virology") and Paul's accusation two months later that Fauci had lied to Congress, followed by a formal criminal referral to the Department of Justice under 18 U.S.C. § 1001.

Four to five major points of contention recur across the entire record. First, **gain-of-function definitions**: whether the EcoHealth/WIV work met the definition of gain-of-function research — Fauci and NIH maintained it did not under the operative P3CO/ePPP framework; Paul, citing Rutgers biologist Richard Ebright, maintained it "unequivocally" did under the 2014 funding-pause definition. Second, **COVID-19 origins**: Fauci consistently said a natural origin was more likely while favoring continued investigation; Paul increasingly argued the evidence pointed to a lab incident and alleged a cover-up. Third, **public-health policy**: masks, school closures, lockdowns, natural immunity, vaccine mandates, and early treatments, on which Paul accused Fauci of ignoring contrary science and Fauci accused Paul of misrepresenting it. Fourth, **records and transparency**: from 2023 onward, the focus widened to alleged evasion of FOIA and destruction of records by Fauci's senior advisor David Morens and, allegedly, by Fauci himself. Fifth, **accountability mechanisms**: Paul's criminal referrals (July 2021, July 2023, renewed July 2025), the January 2025 presidential pardon of Fauci, and the five-year statute of limitations on the May 11, 2021 testimony, which expired May 11, 2026 without charges.

The escalation proceeded in distinct phases. In 2020 the exchanges were heated but conventionally political. In 2021 Paul moved to felony accusations and a DOJ referral; Fauci responded with "you do not know what you are talking about" and "if anybody is lying here, Senator, it is you." In 2022 the January 11 hearing became explicitly personal: Fauci accused Paul of "kindling the crazies" and endangering his family, holding up a printout of Paul's "fire Dr. Fauci" fundraising page. After Fauci retired in December 2022, the venue shifted to the House Select Subcommittee on the Coronavirus Pandemic, whose January 2024 transcribed interviews and June 3, 2024 public hearing produced Fauci's "it sort of just appeared" six-feet answer and his "operative definition" defense of the 2021 testimony. In 2025, Paul became HSGAC chairman, subpoenaed 14 agencies, and renewed his criminal referral after President Biden's preemptive pardon of Fauci; in 2026, after six months of negotiations with Fauci's lawyers collapsed, Paul subpoenaed him on June 22, released a tranche of documents culminating in "Tony's Diary" (1,141 pages of Fauci's private pandemic-era notes) on July 25, and scheduled Fauci's first Senate testimony since 2022.

As of July 28, 2026, matters stand as follows: Fauci is subpoenaed to testify publicly before HSGAC at 8:30 a.m. on July 29, 2026, as the sole listed witness. The § 1001 limitations period on his May 11, 2021 testimony has expired without indictment; his former advisor David Morens was indicted by DOJ in April 2026. The 2025 presidential pardon covers any federal offenses through January 19, 2025, but — as Paul and legal analysts have noted — would not cover any statements made at the July 29 hearing itself. Fauci has made no public statement in 2026 and declined to comment on the diary release. Neither side has retreated from its core positions.

---

## Detailed Chronological Timeline

## 2011–2019: Background

**December 30, 2011 — Fauci co-authors Washington Post op-ed defending H5N1 gain-of-function research.**

Context: After NIH-funded work by Fouchier (Erasmus) and Kawaoka (Wisconsin) engineered H5N1 avian influenza transmissible among ferrets, the National Science Advisory Board for Biosecurity (NSABB) initially recommended redacting the papers. Fauci (NIAID Director), Gary Nabel, and Francis Collins defended the research. This is the policy backdrop Paul would later invoke against Fauci.

Key statements: Fauci, Nabel, and Collins, ["A flu virus risk worth taking," Washington Post, Dec. 30, 2011](https://www.washingtonpost.com/opinions/a-flu-virus-risk-worth-taking/2011/12/30/gIQAM9sNRP_story.html) (paywalled; headline, date, and authors verified via multiple scholarly citations; full text not opened). Fauci also authored "Research on Highly Pathogenic H5N1 Influenza Virus: The Way Forward," *mBio* 3(5) (Sept–Oct 2012), and testified before Senate HSGAC on dual-use research on April 26, 2012 (citation located in secondary literature; original testimony not opened — UNVERIFIED in detail).

**October 16–17, 2014 — White House/NIH gain-of-function funding pause.**

Context: Following biosafety lapses and the gain-of-function controversy, the White House Office of Science and Technology Policy announced a "deliberative process" and a pause on new federal funding for GOF studies "anticipated to enhance the pathogenicity or transmissibility among mammals by respiratory droplets of influenza, MERS, or SARS viruses" ([NIH Office of Science Policy summary](https://osp.od.nih.gov/policies/national-science-advisory-board-for-biosecurity-nsabb/gain-of-function-research/)). The public announcement was the Obama White House blog, Oct. 17, 2014, ["Doing Diligence to Assess the Risks and Benefits of Life Sciences Gain-of-Function Research"](https://obamawhitehouse.archives.gov/blog/2014/10/17/doing-diligence-assess-risks-and-benefits-life-sciences-gain-function-research). The pause applied to new funding; existing grantees were asked to pause voluntarily. Some already-funded experiments were allowed to continue — e.g., the Menachery/Baric SHC014 chimera work at UNC, whose 2015 *Nature Medicine* paper states the experiments "were initiated and performed before the GOF research funding pause."

**June 1, 2014 — NIAID awards grant R01AI110964 to EcoHealth Alliance, including a Wuhan Institute of Virology subaward.**

Context: "Understanding the Risk of Bat Coronavirus Emergence," PI Peter Daszak, administered by NIAID (Fauci, Director). Award history pulled live from the NIH RePORTER v2 API on 2026-07-28:

| Fiscal year | Segment | Amount |
|---|---|---|
| 2014 | 1R01AI110964-01 | $666,442 |
| 2015 | -02 | $630,445 |
| 2016 | -03 | $611,090 |
| 2017 | -04 | $597,112 |
| 2018 | -05 | $581,646 |
| 2019 | 2R01AI110964-06 (competing renewal, "Type 2") | $661,980 |
| 2023 | 5R01AI110964-07 (reinstated) | $576,290 |

Project start June 1, 2014. Subawards (per HHS OIG report A-05-21-00025, Jan. 2023, Table 7): **Wuhan Institute of Virology, $598,611 (06/01/2014–05/31/2019)**; Wuhan University School of Public Health, $201,221. The OIG found 3 NIH awards to EcoHealth totaled ~$8.0M with $1.8M in subawards to 8 subrecipients. The 2019 renewal was awarded under the Trump administration (July 2019, per [Politico, Apr. 27, 2020](https://www.politico.com/news/2020/04/27/trump-cuts-research-bat-human-virus-china-213076)). See the Funding and Grant Record section for the full verified data spine.

**2016 — NIAID reviews R01AI110964 against the GoF pause and determines it is NOT subject.**

Context: Per the OIG report (pp. 10–12): On May 28, 2016, NIAID notified EcoHealth that, based on its Year-2 progress report, "NIAID had determined that the research could be gain-of-function and subject to the funding pause." EcoHealth responded June 8, 2016, arguing the work was unlikely to have pathogenic potential and committing to stop experiments and notify NIH if recombinant viruses showed enhanced growth >1 log over the parental strain. NIH accepted this, concluded the grant was **not subject to the pause**, and added the stop-and-report benchmark as a special term (the July 7, 2016 NIAID letter is quoted verbatim in the House Oversight [Action Referral Memorandum](https://oversight.house.gov/wp-content/uploads/2025/01/ARM_EHA_1.17.2025_Redacted.pdf)). After 2017, NIH also declined to refer any of the three EcoHealth awards for HHS P3CO review. CRS R47114 (["Oversight of Gain-of-Function Research with Pathogens"](https://www.congress.gov/crs-product/R47114)): "NIH reportedly concluded that the research project did not meet the criteria of the 2014 pause on GOF research or the 2017 HHS P3CO guidance."

**January 9 / December 19, 2017 — P3CO guidance issued; pause lifted.**

Context: OSTP issued the P3CO "Recommended Policy Guidance" on Jan. 9, 2017; HHS published its implementing "Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens" on Dec. 19, 2017, lifting the pause (dates verified in the OIG report and NIH OSP page). NIH Director Collins' statement: ["NIH Lifts Funding Pause on Gain-of-Function Research"](https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-lifts-funding-pause-gain-function-research) (Dec. 19, 2017).

---

## 2020

**March 22, 2020 — Paul announces he tested positive for COVID-19.**

Context: Paul was the first U.S. senator known to test positive; he had voted and attended the Senate gym while awaiting results, drawing criticism. The episode— preview truncated; use search to jump to passages —